Related Experiment Video
Updated: Feb 20, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
In Vitro Antileukemic Activity of Formamidine Epidoxorubicin Analogs
Lidia Mazur1, Małgorzata Opydo-Chanek2, Katarzyna Śladowska2
1Department of Experimental Hematology, Institute of Zoology and Biomedical Research, Jagiellonian University, Krakow, Poland lidia.mazur@uj.edu.pl.
Background/Aim:
Epidoxorubicin is an anthracycline agent. The present study was undertaken to compare the antileukemic potential of epidoxorubicin and its two formamidine analogs containing either a morpholine moiety (EPIFmor) or a hexamethyleneimine moiety (EPIFhex) in the amidine group.
Materials And Methods:
The experiments were performed in vitro on MOLT-4 cells using spectrophotometry, Coulter electrical impedance, flow cytometry, and light microscopy methods.
Results:
The leukemia cell responses to the action of the anthracyclines were manifested in their different viability, count and volume, degree of apoptosis and necrosis, activity of caspases -8, -9, and -3/7, mitochondrial membrane potential, and in the cell-cycle distribution. In general, epidoxorubicin appeared to be the most active, and EPIFmor was more active than EPIFhex against MOLT-4 cells.
Conclusion:
The structural modifications of epidoxorubicin in the amidine group were responsible for the varied action of its formamidine analogs on human acute lymphoblastic leukemia cells.
